Quarterly report pursuant to Section 13 or 15(d)

Business combinations - Proforma Information (Details)

v3.23.3
Business combinations - Proforma Information (Details) - USD ($)
3 Months Ended 5 Months Ended 9 Months Ended
Jun. 01, 2023
Sep. 30, 2023
Sep. 30, 2022
May 31, 2023
Sep. 30, 2023
Sep. 30, 2022
Merger with TCR2 Therapeutics Inc.            
Gain on bargain purchase         $ 22,049,000  
Share-based compensation expense   $ 3,183,000 $ 3,663,000   8,696,000 $ 14,294,000
TCR2 Therapeutics            
Merger with TCR2 Therapeutics Inc.            
Revenue         60,050 16,120
Net loss         (129,684) (214,680)
Acquisition-related costs incurred by TCR2         9,000,000.0  
Gain on bargain purchase $ 22,049,000       22,000,000.0  
Acquisition-related costs         $ 7,346,000  
Share-based compensation expense       $ 1,000,000.0   $ 8,700,000